Embed Size (px)
Citation preview
Name
Page 1Name: Nashwa Jarkas, Ph.D.
Address: 2750 Carmon on Wesley, NWAtlanta, GA 30327404-355-6079404-213-3398 (mobile)
E-mail Address: [email protected]
Citizenship: USA Citizen
Current Titles and Affiliations: Ph.D. in synthetic organic-heterocyclic chemistry (major in medicinal and pharmaceutical chemistry)
Academic Appointments: Primary Appointments: assistant professor, research track, department of Radiology and Imaging Sciences, Emory University School of Medicine, CSI, July 2008-August 2014
Previous Academic and Professional Appointments: senior research associate, department of Radiology, Emory University School of Medicine, September 2002-June 2008
Education:
1988-1991: License de Mesures et Contrôles en Chimie at the University of Metz, France(equivalent to BS degree)
1992: Maîtrise de Mesures et Contrôles en Chimie at the University of Metz, France(equivalent to MS degree)
1993: DEA de Chimie et Physico-chimie Moléculaires at the University of Metz, France(one year pre-doctoral qualification). Dr. Gilbert Kirsch
1994-1997: Four years of PhD in synthetic organic-heterocyclic chemistry in the organic chemistry laboratory at the University of Metz, France. Ph.D. obtained on July 9th 1997 with Honors Degree. Dr. Gilbert KirschThesis: synthesis of biheterocyclic analogues of ellipticine starting with benzo[b]furan, thiophene, and selenophene
2015: Clinical Research Associate (CRA) Certification. Clinical Research Training Online.
Name
Page 2Teaching:
1994-1997: Department of Chemistry, University of Metz, Metz, FranceDuring my PhD, I had done some undergraduate laboratory course teaching.
Postgraduate Training:
1998-2002 Postdoctoral fellowship in radio-pharmaceutical chemistry in the P.E.T. chemistry center of Emory University in Atlanta, Georgia, USA. Dr. Mark M. Goodman
2002-2008 Senior research associate in radio-pharmaceutical chemistry in the P.E.T chemistry center of Emory University in Atlanta, Georgia, USA. Dr. Mark M. Goodman
2008-2014 Assistant professor in radio-pharmaceutical chemistry at the Emory Center for Systems Imaging (CSI) in Atlanta, Georgia, USA. Dr. Mark M. Goodman
Manuscript Review:
“PET Imaging of the AT1 Receptor with 11C KR31173 in mice, dogs and baboons”, Journal of Nuclear Medicine, 2004
“FlipADAM: a potential new SPECT imaging agent for the serotonin transporter”, Nuclear Medicine and Biology, 2010
“Microwave assisted synthesis and in silico screening of steroidal pyrazolines”, Spectroscopy Letters, 2012
“Characterization of FlipIDAM as a SERT-selective imaging agent”, Nuclear Medicine and Biology, 2012
“Trans-1-amino-3-18F-fluorocyclobutanecarboxylic acid (anti-18F-FACBC) is a feasible alternative to 11C-methyl-L-methionine and magnetic resonance imaging for monitoring treatment response in gliomas”, Nuclear Medicine and Biology, 2013
“Characterization of FlipIDAM as a SERT-selective SPECT imaging agent”, Nuclear Medicine and Biology, 2013
“An improved preparation of [18F]FPBM: a potential serotonin transporter (SERT) imaging agent”, Nuclear Medicine and Biology, 2013
Honors and Awards:
Name
Page 3
I received a K01 Career Development Award for young mentored scientists from NIH-NIMH. Title ‘New PET ligands for brain serotonin transporter in neuropsychiatric disorders’. Grant: K01-MH090278 (PI: Jarkas). Year: 07/01/2010-05/31/2013. K01 no cost extension: 06/01/2013-05/31/2014
I was the first place winner out of seven finalists of the Radiopharmaceutical Sciences Council Young Investigator Award presented at the Society of Nuclear Medicine Meeting in New Orleans in June 2003
I was one of six finalists of the Emory University School of Medicine Department of Radiology and Imaging Sciences Rising Star Award in 2011
Society Memberships:
American Chemical Society (ACS). 1998-2014Society of Nuclear Medicine and Molecular Imaging (SNMMI). 2002-2014Radiopharmaceutical Science Council (RPSC). 2004-2014Society of Radiopharmaceutical Sciences (SRS). 2005-2014Center for Molecular Imaging Innovation and Translation (CMIIT). 2012-2014PET Center of Excellence. 2012-2014Brain Imaging Council (BIC). 2013-2014
Research Focus:
Neuroscience:
The development of carbon-11 and/or fluorine-18 biochemical probes that could be used clinically
to provide information, using medical imaging, to study alterations in brain chemistry associated with
many neuropsychiatric disorders and cocaine addiction. This project led to the translation of the best
carbon-11 serotonin transporter radiotracer, [11C]HOMADAM, from benchside to bedside.
Oncology:
The synthesis and fluorine-18 labeling of the different enantiomers of the non-natural amino-acid,
1-amino-2-fluorocyclopentane carboxylic acid ([18F]FACPC) for tumor imaging. The major
accomplishments of that project included the characterization of different kind of tumors in cells, mice,
and rats with both [18F]FACPC enantiomers and the translation of the lead enantiomer anti-(R,R)-2-
[18F]FACPC to healthy and non-healthy human imaging.
Name
Page 4
Grant Support:
a. Active Support: N/A
b. Previous Support:
I. Private foundation funded:
Investigator status: Chemist (Co-Investigator)
Source: Georgia Research Alliance, GRA VENTURE LAB GRANT GRA, VL09, C7
Title: GRA.VL09.C7, PI: Goodman
Award type: innovative research: the goal of this Venture Lab project was to demonstrate that PET with anti-2-[18F]FACPC will lead to improve patient care in the diagnosis and staging of prostate carcinoma.
Amount: $ 50,000
Year: 01/01/2009-01/31/2010
II. Federal funded:
Investigator status: Principal Investigator
Source: NIH-NIMH (Grant No: K01MH090278), PI: Jarkas
Title: New PET ligands for brain serotonin transporter in neuropsychiatric disorders
Award type: K01 Career Development Award for young mentored scientists
Amount: $170,000/year
Year: 07/01/2010-05/31/2013
c. Pending Support: N/A
Clinical Service Contributions:
1) [11C]HOMADAM human studies
Name
Page 52) Anti-(R,R)-2-[18F]FACPC human studies
Lectureships, Seminar Invitations, and Visiting Professorships:
Research in Progress Seminar: Emory University, School of Medicine, “New SPECT and PET Agents for In Vivo Study of Serotonin Transporter Sites in Psychiatric Disorders and Cocaine Addiction”, 2007.
Research in Progress Seminar: Emory University, School of Medicine, “Characterization of anti-18F-FACPC and its Enantiomers as PET Tumor Imaging Agents”, 2010.
Research in Progress Seminar: Emory University, School of Medicine, “Developing (a) potent fluorine-18 HOMADAM derivative(s) to image the human brain SERT: how far are we from our destination?”, 2011.
Research in Progress Seminar: Emory University, School of Medicine, “Fluorine-18 fluoroalkoxy benzylamines to image the brain serotonin transporter”, 2012.
Professional Service:
Effective participation in the blue, gold, and green committees of Emory IACUC office as a Scientific Member. My responsibilities include:
- Reviewing IACUC protocols submitted from the different departments of Emory University and Hospital locations and all other Emory affiliations as well as Yerkes.
- Reviewing any new business discussed within the IACUC meetings.
- Participating in the IACUC protocol review meetings.
- Participating in the IACUC business meetings.
- Participating in the IACUC site inspections of all the different departments of Emory University and Hospital locations and all other Emory affiliations as well as Yerkes.
Participation in national and international meetings
Served as a member of the Center for Molecular Imaging Innovation and Translation (CMIIT) Editorial Board Task Force. The Editorial Board:
Name
Page 6- Oversees the production of the Molecular Imaging (MI) Gateway newsletter (members serve as editors of specific issues on a rotating basis)
- Assists in assigning authors for focus on MI (in Newsline) if requested
- Consults on authors/topics for focus on MI in the Journal of Nuclear Medicine (JNM) and in the Molecular Imaging Journal
- Reviews monthly MI references, selecting the best to be highlighted in the monthly CMIIT email blast and on the website
- Provides images for Image of the Month feature (website) and for use in other publications and marketing materials
- Monitors and identifies issues in assigned areas and recommend appropriate actions, policies, and programs to the CMIIT’s Board of Directors.
Bibliography:
a. Published and Accepted Research Articles (Clinical, Basic Science, Other) in Refereed Journals:
1) Nachwa Jarkas, Gilbert Kirsch, and Pierre Seck. 1997, "Synthesis of new biheterocyclic analogs of pyridocarbazoles". Heterocyclic Communications, 3, 65-72.
2) Nachwa Jarkas, Gilbert Kirsch, and Pierre Seck. 1998, "New heterocyclic analogs of pyridocarbazoles from azidoacrylates". Heterocyclic Communications, 4, 227-234.
3) Nachwa Jarkas, Delphine Joseph, Hervé Royer, and Gilbert Kirsch . 1998, "Some new selenium containing analogs of pyridocarbazoles and indolocarbazoles". Phosphorus, Sulphur and Silicon, 136, 137 & 138, 353-356.
4) Stéphanie Deprets, Nachwa Jarkas, and Gilbert Kirsch . 1999, "New synthetic uses of 3-oxo-benzo[b]thiophenes". Phosphorus, Sulphur and Silicon, 153 & 154, 401-402.
5) Nachwa Jarkas, Jonathan McConathy, John R. Votaw, Ronald J. Voll, Eugene Malveaux, Vernon M. Camp, Larry Williams, Robin R. Goodman, Clinton D. Kilts, Mark M. Goodman. 2005, "Synthesis and characterization of EADAM: a selective radioligand for mapping the brain serotonin transporters by positron emission tomography". Nuclear Medicine and Biology, 32, 75-86.
6) Nachwa Jarkas, John R. Votaw, Ronald J. Voll, Larry Williams, Vernon M. Camp, Michael J. Owens, David C. Purselle, J. Douglas Bremner, Clinton D. Kilts, Charles B. Nemeroff, Mark M. Goodman. 2005,
Name
Page 7"Carbon-11 HOMADAM: a novel PET radiotracer for imaging serotonin transporters". Nuclear Medicine and Biology, 32, 211-224.
7) Nachwa Jarkas, Jonathan McConathy, Ronald J. Voll, Mark M. Goodman. 2005, "Synthesis, in vitro characterization and radiolabeling of N,N-dimethyl-2-(2’-amino-4’-substituted-phenylthio)benzylamines, potential candidates as selective serotonin transporter radioligands". Journal of Medicinal Chemistry, 48, 4254-4265.
8) Jeffrey S. Stehouwer, Christophe Plisson, Nachwa Jarkas, Fanxing Zeng, Ronald J. Voll, Larry Williams, Laurent Martarello, John R. Votaw, Gilles Tamagnan, and Mark M. Goodman. 2005, "Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 (N-fluoroalkyl) labeled 2-carbomethoxy-3-(4’-(3-furyl)phenyl)-tropanes and nortropanes: candidate rdioligands for in Vivo Imaging of the serotonin transporter with positron emission tomography”. Journal of Medicinal Chemistry, 48, 7080-7083.
9) Christophe Plisson, Nachwa Jarkas, Jon McConathy, Ronald J. Voll, John Votaw, Larry Williams, Leonard L. Howell, Clinton D. Kilts, and Mark M. Goodman. 2006, "Evaluation of carbon-11-labeled 2-carbomethoxy-3-[4’-((Z)-2-iodoethenyl)phenyl]nortropane as a potential radioligand for imaging the serotonin transporter by PET”. Journal of Medicinal Chemistry, 49, 942-946.
10) Fanxing Zeng, Nachwa Jarkas, Michael J. Owens, Clinton D. Kilts, Charles B. Nemeroff and Mark M. Goodman. 2006, “Synthesis and monoamine transporter affinity of front bridged tricyclic 3-(4’-halo or 4’-methyl)phenyltropanes bearing methylene or carbomethoxymehtylene on the bridge to the 2-position”. Bioorganic and Medicinal Chemistry Letters, 16, 4661-4663.
11) Jeffrey S. Stehouwer, Nachwa Jarkas, Fanxing Zeng, Ronald J. Voll, Larry Williams, Michael J. Owens, John R. Votaw, and Mark M. Goodman. 2006, "Synthesis, radiosynthesis, and biological evaluation of carbon-11 labeled 2-carbomethoxy-3-(3’((Z)2-haloethenyl)phenyl)nortropanes: candidate radioligands for in vivo imaging of the serotonin transporter with positron emission tomography”. Journal of Medicinal Chemistry, 49, 6760-6767.
12) Gilles D. Tamagnan, Eric Brenner, David Alagille, Julie K. Staley, Colin Haile, Andrei Koren, Michelle Early, Ronald M. Baldwin, Frank I. Tarazi, Ross J. Baldessarini, Nachwa Jarkas, Mark M. Goodman and John P. Seibyl. 2007, “Development of SPECT imaging agents for the norepinephrine transporters: [123I]INER”. Bioorganic and Medicinal Chemistry Letters, 17, 533-537.
13) Fanxing Zeng, Jeffrey S. Stehouwer, Nachwa Jarkas, Ronald J. Voll, Larry Williams, Vernon M. Camp, John R. Votaw, Michael J. Owens, Clinton D. Kilts, Charles B. Nemeroff and Mark M. Goodman. 2007, “Synthesis and biological evaluation of 2,3-(substituted phenyl) nortropanes as potential norepinephrine transporter imaging agents”. Bioorganic and Medicinal Chemistry Letters, 17, 3044-3047.
Name
Page 8
14) Jonathan McConathy, Catherine Capello, Nachwa Jarkas, Zachary N. Stowe and Michael J. Owens. 2007, “Preparation of antidepressants for use in preclinical research”. International Journal of Neuropsychopharmacology, 10, 759-763.
15) Nachwa Jarkas, Ronald J. Voll, Larry Williams, John R. Votaw, Mike Owens, and Mark M. Goodman. 2008, "Synthesis and in vivo evaluation of halogenated N,N-dimethyl-2-(2’-amino-4’-hydroxymethylphenylthio)benzylamine derivatives as PET serotonin transporter radioligands ". Journal of Medicinal Chemistry, 51, 271-281.
16) Fanxing Zeng, Nachwa Jarkas, Jeffrey S. Stehouwer, Ronald J. Voll, Michael J. Owens, Clinton D. Kilts, Charles B. Nemeroff and Mark M. Goodman. 2008, “Synthesis, in vitro characterization, and radiolabeling of reboxetine analogs as potential PET radioligands for imaging the norepinephrine transporter”. Bioorganic and Medicinal Chemistry, 16, 783-793.
17) Jeffrey S. Stehouwer, Nachwa Jarkas, Fanxing Zeng, Ronald J. Voll, Larry Williams, Vernon M. Camp, Eugene J. Malveaux, John R. Votaw, Leonard Howell, Michael J. Owens, and Mark M. Goodman. 2008, "Synthesis, radiosynthesis, and biological evaluation of fluorine-18 labeled 2-Carbo(fluoroalkoxy)-3-(3’-((Z)-2-haloethenyl)phenyl)nortropanes: candidate radioligands for in Vivo imaging of the serotonin transporter with positron emission tomography”. Journal of Medicinal Chemistry, 51, 7788-7799.
18) Jonathan A. Nye, John R. Votaw, Nachwa Jarkas, David Purselle, Vernon Camp, James D. Bremner, Clinton D. Kilts, Charles B. Nemeroff, and Mark M. Goodman. 2008, “Compartmental modeling of 11C-HOMADAM binding to the serotonin transporter in the healthy human brain”. Journal of Nuclear Medicine, 49, 2018-2025.
19) Fanxing Zeng, Jiyoung Mun, Nachwa Jarkas, Jeffrey S. Stehouwer, Ronald J. Voll, Gilles D. Tamagnan, Leonard Howell, John R. Votaw, Clinton D. Kilts, Charles B. Nemeroff and Mark M. Goodman. 2009, “Synthesis, radiosynthesis, and biological evaluation of carbon-11 and fluorine-18 labeled reboxetine analogues: potential positron emission tomography radioligands for in vivo imaging the norepinephrine transporter”. Journal of Medicinal Chemistry, 52, 62-73.
20) Nachwa Jarkas, Ronald J. Voll, Larry Williams, and Mark M. Goodman. 2010, "Validation of two fluoro-analogues of N,N-dimethyl-2-(2’-amino-4’-hydroxymethyl-phenylthio)benzylamine as serotonin transporter imaging agents using microPET". Nuclear Medicine and Biology, 37, 593-603.
21) Nachwa Jarkas, Ronald J. Voll, Larry Williams, Vernon M. Camp, and Mark M. Goodman. 2010, "(R,S)-anti-1-amino-2-[18F]fluorocyclopentyl-1-carboxylic acid: synthesis from racemic 2-benzyloxycyclopentanone and biological evaluation for brain tumor imaging with positron emission tomography". Journal of Medicinal Chemistry, 53, 6603-6607.
Name
Page 922) Savir-Baruch B., Schuster DM., Jarkas N., Master VA., Nieh PT., Halkar RK., Nye JA., Lewis MM., Crowe VM., Bellamy LM., Roberts DL., Goodman MM. 2010, “Pilot evaluation of anti-1-amino-2-[18F] fluorocyclopentane-1-carboxylic acid (anti-2-[18F]FACPC) PET-CT in recurrent prostate carcinoma”. Molecular Imaging and Biology, 13 (6), 1272-77.
23) Jonathan A. Nye, Nashwa Jarkas, David M. Schuster, Bital Savir-Baruch, Ronald J. Voll, Vernon M. Camp, Mark M. Goodman. 2011, “Biodistribution and human dosimetry of enantiomer-1 of the synthetic leucine analog anti-1-amino-2-fluorocyclopentyl-1-carboxylic acid”. Nuclear Medicine and Biology, 38, 1035-1041.
24) Nashwa Jarkas, Ronald J. Voll, Mark M. Goodman. 2013, “Synthesis of a phenolic precursor and its efficient O-[18F]fluoroethylation with purified no-carrier added [18F]2-fluoroethyl brosylate as the labeling agent”. Journal of Labelled Compounds and Radiopharmaceuticals, 56 (11), 539-543.
b. Manuscripts Submitted:N/A
c. Symposium Contributions:
1) N. Jarkas, T. Ely, C. D. Kilts and M. M. Goodman. "Synthesis of new fluoroalkyl derivatives of ADAM, potential radiotracers for mapping serotonin transporters (SERT) by PET". The IV International Symposium on Radiohalogens, Whistler-B.C., CANADA, September 2000.
2) N. Jarkas, J. McConathy, T. Ely, C. D. Kilts, J. R. Votaw and M. M. Goodman. "Synthesis and radiolabeling of new derivatives of ADAM, potential candidates as SERT imaging agents for PET". 14 th
International Symposium of Radiopharmaceutical Chemistry, Interlaken, SWITZERLAND, June 2001.
3) N. Jarkas, J. McConathy, L. Martarello, T. Ely, C. D. Kilts, J. R. Votaw and M. M. Goodman. "Synthesis, characterization and radiolabeling of new derivatives of ADAM, potential radiotracers for mapping serotonin transporters (SERT) by PET". 48th Annual Society of Nuclear Medicine Meeting, Toronto, CANADA, June 2001.
4) N. Jarkas, J. McConathy, E. Malveaux, J. R. Votaw and M. M. Goodman. "Radiolabeling and in vivo characterization of 11C-EADAM: an attractive PET radioligand for serotonin transporters (SERT)". 49 th
Annual Society of Nuclear Medicine Meeting, Los Angeles, CALIFORNIA, June 2002. 5) N. Jarkas, J. McConathy, E. J. Malveaux, L. A. Williams, J. R. Votaw, C. D. Kilts and M. M. Goodman. "Synthesis, characterization and microPET imaging of serotonin transporters (SERT) with [11C]-HOMADAM: a new diarylsulfide SERT PET imaging agent". 50 th Annual Society of Nuclear Medicine Meeting, New Orleans, LOUISIANA, June 2003.
Name
Page 10
6) N. Jarkas, J. McConathy, C. Plisson, R. Voll, L. A. Williams, J. R. Votaw and M. M. Goodman. "Carbon-11 labeled 4'-substituted ADAM analogues for mapping the serotonin transporter (SERT) by PET". 15th International Symposium of Radiopharmaceutical Chemistry, Sydney, AUSTRALIA, August 2003.
7) C. Plisson, J. McConathy, N. Jarkas, R. Voll, J. R. Votaw, L. A. Williams and M. M. Goodman. "New serotonin transporter PET imaging agent: [18F]FEZIENT". 15th International Symposium of Radiopharmaceutical Chemistry, Sydney, AUSTRALIA, August 2003.
8) N. Jarkas, C. Plisson, R. J. Voll, L. A. Williams, J. R. Votaw and M. M. Goodman. "Preparation and pharmacological characterization of a new serotonin transporter (SERT) PET imaging agent: [11C]FMADAM". 51th Annual Society of Nuclear Medicine Meeting, Philadelphia, PENNSYLVANIA, June 2004.
9) J. S. Stehouwer, N. Jarkas, C. Plisson, R. J. Voll, J. R. Votaw, L. A. Williams, G. D. Tamagnan and M. M. Goodman. "Micropet imaging of the brain serotonin transporter (SERT) in non-human primates with [11C]3FPNT". 51th Annual Society of Nuclear Medicine Meeting, Philadelphia, PENNSYLVANIA, June 2004.
10) C. Plisson, N. Jarkas, J. McConathy, R. J. Voll, J. Votaw, L. Williams and M. M. Goodman. "Synthesis, characterization and microPET imaging [18F]FEZIENT, [18F]FPZIENT, and [18F]FEZBrENT: new serotonin transporter (SERT) imaging agents". 51th Annual Society of Nuclear Medicine Meeting, Philadelphia, PENNSYLVANIA, June 2004.
11) F. Zeng, R. J. Voll, N. Jarkas, J. R. Votaw L. Williams, V. M. Camp and M. M. Goodman. "Synthesis of a 18F-labeled phenyl-imidazo[1,2-A]pyridine analog as a potential agent for imaging -amyloid in Alzheimer’s disease". 51th Annual Society of Nuclear Medicine Meeting, Philadelphia, PENNSYLVANIA, June 2004.
12) J. Votaw, N. Jarkas, R. Voll, C. Kilts, C. Nemeroff, M. Goodman. “Measuring SERT occupancy with [C-11]HOMADAM and PET following cialopram challenge: determination of error and validation of method”. 5th International Symposium on Functional Neuroreceptor Mapping of the Living Brain, Vancouver, CANADA, July 2004. 13) N. Jarkas, R. J. Voll, L. A. Williams, J. R. Votaw, M. M. Goodman. "The PET imaging agent [11C]BFHOMADAM as a new ligand for the serotonin transporters (SERT)". 52sd Annual Society of Nuclear Medicine Meeting, Toronto, CANADA, June 2005.
14) N. Jarkas, R. J. Voll, L. A. Williams, J. R. Votaw, M. M. Goodman. "Synthesis, radiosynthesis and in vivo imaging studies comparing three C-11 labeled PET ligands for mapping the serotonin transporter (SERT)". 16th International Symposium of Radiopharmaceutical Chemistry, Iowa city, IOWA, June 2005.
Name
Page 11
15) J. S. Stehouwer, N. Jarkas, F. Zeng, R. J. Voll, L. Williams, J. R. Votaw, M. M. Goodman. "Micropet imaging of the brain serotonin transporter with [11C]mZIENT". 16th International Symposium of Radiopharmaceutical Chemistry, Iowa city, IOWA, June 2005.
16) Jeffrey S. Stehouwer, Nachwa Jarkas, Fanxing Zeng, Ronald J. Voll, Larry Williams, John R. Votaw, and Mark M. Goodman. "MicroPET imaging of the brain serotonin transporter with [11C]mZBrENT". The 231st American Chemical Society National Meeting, Atlanta, Georgia, March 26-30, 2006.
17) Fanxing Zeng, Nachwa Jarkas, Jeffrey S. Stehouwer, Ronald J. Voll, Larry Williams, John R. Votaw, and Mark M. Goodman. "Synthesis and biological evaluation of carbon-11 labeled 2-carbomethoxy-3-fluoro-4’-methylphenyl)-nortropane: Candidate PET ligand for the norepinephrine transporter". The 231st
American Chemical Society National Meeting, Atlanta, Georgia, March 26-30, 2006.
18) J. Stehouwer, N. Jarkas, F. Zeng, R. Voll, L. Williams, J. Votaw, M. Goodman. "MicroPET imaging of the brain serotonin transporter with [18F]FEmZIENT". 53sd Annual Society of Nuclear Medicine Meeting, San Diego, CALIFORNIA, June 2006.
19) M. M. Goodman, N. Jarkas, J. R. Votaw, R. J. Voll, D. C. Purselle, C. D. Kilts, J. D. Bremner, C. C. Meltzer, C. B. Nemeroff. "Initial experience of high resolution brain PET imaging of human serotonin transporters (SERT) with [11C]HOMADAM". 53sd Annual Society of Nuclear Medicine Meeting, San Diego, CALIFORNIA, June 2006.
20) F. Zeng, N. Jarkas, J. S. Stehouwer, R. J. Voll, M. J. Owens, G. Tamagnan, L. Williams, J. R. Votaw, M. M. Goodman. "Synthesis and evaluation of a C-11 labeled reboxetine analog as a norepinephrine transporter imaging agent". 53sd Annual Society of Nuclear Medicine Meeting, San Diego, CALIFORNIA, June 2006.
21) M. Goodman, J. Stehouwer, N. Jarkas, R. Voll, L. Williams, J. Votaw. "In vivo characterization in non-human primates of beta FEmZIENT and beta FEmZBrENT: new serotonin transporter imaging agents: effects of selective monoamine transporter displacement using microPET". 6th International Symposium on Neuroreceptor Mapping, Copenhagen, DENMARK, July 2006.
22) F. Zeng, N. Jarkas, R. J. Voll, L. Williams, J. R. Votaw, L. Howell, C. D. Kilts, C. Nemeroff, M. M. Goodman. "Synthesis, characterization and in vivo pet imaging in non-human primates of [11C] (S,S)-MSREBOX: a new norepinephrine transporter imaging agent". Annual Congress of the European Association of Nuclear Medicine Meeting, Athens, GREECE, September-October, 2006.
Name
Page 12
23) N. Jarkas, R. J. Voll, L. A. Williams, J. R. Votaw, M. M. Goodman. "Synthesis and evaluation of a serotonin transporter ligand (SERT) PET imaging agent: [11C]BrHOMADAM". 17th International Symposium of Radiopharmaceutical Chemistry, Aachen, GERMANY, April-May 2007.
24) F. Zeng, N. Jarkas, J. S. Stehouwer, R. J. Voll, L. A. Williams, J. R. Votaw, M. M. Goodman. "Synthesis and evaluation of (S, S)-[11C]METREBOX as a norepinephrine transporter imaging agent ". 17th International Symposium of Radiopharmaceutical Chemistry, Aachen, GERMANY, April-May 2007.
25) F. Zeng, N. Jarkas, J. S. Stehouwer, L. Williams, J. R. Votaw, C. D. Kilts, C. B. Nemeroff, M. M. Goodman. "18F-Labeled analogs of reboxetine as PET imaging agents for norepinephrine transporters". 54th Annual Society of Nuclear Medicine Meeting, Washington DC, June 2007.
26) F. Zeng, J. Mun, N. Jarkas, J. S. Stehouwer, R. J. Voll, L. Williams, J. R. Votaw, L. Howell, M. M. Goodman. "Synthesis and evaluation of (S, S)-[11C]SMENET as a norepinephrine transporter imaging agent". 55th Annual Society of Nuclear Medicine Meeting, New Orleans, LOUISIANA, June 2008.
27) J. A. Nye, J. R. Votaw, N. Jarkas, D. Purselle, V. Camp, J. Bremner, M. Goodman. "Modeling of [11C]HOMADAM binding to the serotonin transporters (SERT) in healthy humans". 55th Annual Society of Nuclear Medicine Meeting, New Orleans, LOUISIANA, June 2008.
28) J. A. Nye, J. R. Votaw, N. Jarkas, D. Purselle, V. Camp, J. D. Bremner, M. M. Goodman. "Kinetic modeling of human serotonin transporters with [11C]ZIENT on a high resolution brain tomograph" . 55th
Annual Society of Nuclear Medicine Meeting, New Orleans, LOUISIANA, June 2008.
29) F. Zeng, N. Jarkas, R. J. Voll, J. R. Votaw, L. Howell, C. D. Kilts, C. B. Nemeroff, M. M. Goodman. "MEDI224-Synthesis, characterization and in vivo imaging in nonhuman primates of a series of carbon-11 reboxetine analogs as norepinephrine transporter (NET) PET imaging agents". 236th National Meeting of the American-Chemical-Society, Philadelphia, PENNSYLVENIA, August 2008.
30) N. Jarkas, R. J. Voll, V. M. Camp, L. A. Williams, E. J. Malveaux, M. M. Goodman. "Synthesis of 18F-FACPC and its biological evaluation in 9L gliosarcoma cells and 9L tumor bearing rats". 18 th International Symposium of Radiopharmaceutical Chemistry, Edmonton, Alberta, CANADA, July 2009.
31) N. Jarkas, R. J. Voll, V. M. Camp, Z. Zhang, and M. M. Goodman. "Synthesis and characterization of the two enantiomers of anti-18F-FACPC as PET tumor agents". 57th Annual Society of Nuclear Medicine Meeting, Salt Lake City, UTAH, June 2010.
32) Savir-Baruch Bital, Schuster David M., Jarkas Nachwa, Master Viraj, Nieh Peter T., Halkar Raghuveer K., Nye Jonathan A., Lewis Melinda M., Roberts David L., Goodman Mark M. "Pilot evaluation
Name
Page 13
of 1-amino-2-[18F]fluorocyclopentane-1-carboxylic acid (anti-2-[18F]FACPC) PET-CT in recurrent prostate carcinoma". 57th Annual Society of Nuclear Medicine Meeting, Salt Lake City, UTAH, June 2010.
33) Jonathan A. Nye, Michael Owens, Boadie Dunlop, Nachwa Jarkas, Clint D. Kilts, Charles B. Nemeroff, Mark M. Goodman. “Test-retest reliability of the SERT imaging agent [11C]HOMADAM in healthy humans”. 6th International Symposium on Neuroreceptor Mapping, Glasgow, SCOTLAND, July 2010.
34) Nachwa Jarkas, Ronald J. Voll, Vernon M. Camp, Z. Zhang, and Mark M. Goodman. “Comparison of the biological properties of [18F]FACPC two enantiomers in human cancer cells”. Pacifichem, Honolulu, Hawaii, December 2010.
35) N. Jarkas, R. Voll, V. M. Camp, L. Williams, E. J. Malveaux, Z. Zhang, M. M. Goodman. "Evaluation of 18F-FACPC stereoisomers in human tumors bearing mice". 58th Annual Society of Nuclear Medicine Meeting, San Antonio, Texas, June 2011.
36) Jarkas Nashwa, Voll Ronald J., and Goodman Mark M. "Synthesis of N,N-dimethyl-2-(2’-amino-4’-hydroxymethyl-phenylthio)-5-(2-18F-fluorethoxy)-benzylamine (18F-FEOHOMADAM) as potential radiotracer for SERT". 19th International Symposium of Radiopharmaceutical Chemistry, Amsterdam, NETHERLANDS, September 2011.
37) N. Jarkas, R. J. Voll, M. M. Goodman. "Development of [F-18]FPOHOMADAM as a PET radiotracer for SERT". 59th Annual Society of Nuclear Medicine Meeting, Miami, Florida, June 2012.
38) Jarkas Nashwa, Voll Ronald J., and Goodman Mark M. "Evaluation of FEOHOMADAM as potential PET radiotracer for in vivo imaging of the SERT". 20th International Symposium of Radiopharmaceutical Chemistry, Jeju Island, SOUTH KOREA, May 2013.
39) N. Jarkas. 60th Annual Society of Nuclear Medicine Meeting, Vancouver, Canada, June 2013.
40) N. Jarkas. 2014 Human Amyloid Imaging Meeting, Miami, Florida, January 2014.
41) N. Jarkas, R. J. Voll, M. M. Goodman. "Evaluation of a serotonin transporter (SERT) PET radiotracer: MeOHOMADAM". 60th Annual Society of Nuclear Medicine Meeting, St Louis, Missouri, June 2014.
d. Book Chapters:
N. Jarkas, J. McConathy, T. Ely, C. D. Kilts, J. R. Votaw and M. M. Goodman. 2001, "Synthesis and radiolabeling of new derivatives of ADAM, potential candidates as SERT imaging agents for PET". J. Labelled. Compd. Radiopharm., 44, S204-206.
Name
Page 14
Mark M. Goodman, Christophe Plisson, Nachwa Jarkas, Jonathan McConathy, John R. Votaw, Ronald J. Voll, Clinton D. Kilts. 2003, “Carbon-11 serotonin transporter ligands”. Synthesis and Applications of Isotopically Labeled Compounds, 179-182.
e. Reviews:
Jonathan McConathy, Weiping Yu, Nachwa Jarkas, Wonewoo Soe, David M. Schuster, and Mark M. Goodman. 2012, “Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents”. Medicinal Research Reviews, 32 (4), 868-905.
Nashwa Jarkas. 2013, “Fluorinated Diaryl Sulfides”. Current Topics in Medicinal Chemistry, 13 (8), 936-943.
f. Other Publications (Abstracts):
1) N. Jarkas, J. McConathy, L. Martarello, T. Ely, C. D. Kilts, J. R. Votaw and M. M. Goodman. 2001, "Synthesis, characterization and radiolabeling of new derivatives of ADAM, potential radiotracers for mapping serotonin transporters (SERT) by PET". Journal of Nuclear Medicine, 42, 149P.
2) N. Jarkas, J. McConathy, E. Malveaux, J. R. Votaw and M. M. Goodman. 2002, "Radiolabeling and in vivo characterization of 11C-EADAM: an attractive PET radioligand for serotonin transporters (SERT)". Journal of Nuclear Medicine, 43, 164P.
3) N. Jarkas, J. McConathy, E. J. Malveaux, L. A. Williams, J. R. Votaw, C. D. Kilts and M. M. Goodman. 2003, "Synthesis, characterization and microPET imaging of serotonin transporters (SERT) with [11C]-HOMADAM: a new diarylsulfide SERT PET imaging agent". Journal of Nuclear Medicine, 44, 48P.
4) N. Jarkas, J. McConathy, C. Plisson, R. Voll, L. A. Williams, J. R. Votaw and M. M. Goodman. 2003, "Carbon-11 labeled 4'-substituted ADAM analogues for mapping the serotonin transporter (SERT) by PET". Journal of Labelled Compounds and Radiopharmaceuticals, 46, S169.
5) C. Plisson, J. McConathy, N. Jarkas, R. Voll, J. R. Votaw, L. A. Williams and M. M. Goodman. 2003, "New serotonin transporter PET imaging agent: [18F]FEZIENT". Journal of Labelled Compounds and Radiopharmaceuticals, 46, S170.
6) N. Jarkas, C. Plisson, R. J. Voll, L. A. Williams, J. R. Votaw and M. M. Goodman. 2004, "Preparation and pharmacological characterization of a new serotonin transporter (SERT) PET imaging agent: [11C]FMADAM". Journal of Nuclear Medicine, 45, 439P.
Name
Page 15
7) C. Plisson, N. Jarkas, J. McConathy, R. J. Voll, J. Votaw, L. Williams and M. M. Goodman. 2004, "Synthesis, characterization and microPET imaging [18F]FEZIENT, [18F]FPZIENT, and [18F]FEZBrENT: new serotonin transporter (SERT) imaging agents". Journal of Nuclear Medicine, 45, 107P.
8) J. S. Stehouwer, N. Jarkas, C. Plisson, R. J. Voll, J. R. Votaw, L. A. Williams, G. D. Tamagnan and M. M. Goodman. 2004, "Micropet imaging of the brain serotonin transporter (SERT) in non-human primates with [11C]3FPNT". Journal of Nuclear Medicine, 45, 439P.
9) F. Zeng, R. J. Voll, N. Jarkas, J. R. Votaw L. Williams, V. M. Camp and M. M. Goodman. 2004, "Synthesis of a 18F-labeled phenyl-imidazo[1,2-A]pyridine analog as a potential agent for imaging -amyloid in Alzheimer’s disease". Journal of Nuclear Medicine, 45, 115P.
10) J. Votaw, N. Jarkas, R. Voll, C. Kilts, C. Nemeroff, M. Goodman. 2004, “Measuring SERT occupancy with [C-11]HOMADAM and PET following cialopram challenge: determination of error and validation of method”. Neuroimage, 22 (Suppl. 2), T198.
11) N. Jarkas, R. J. Voll, L. A. Williams, J. R. Votaw, M. M. Goodman. 2005, "The PET imaging agent [11C]BFHOMADAM as a new ligand for the serotonin transporters (SERT)". Journal of Nuclear Medicine, 46, 137P.
12) N. Jarkas, R. J. Voll, L. A. Williams, J. R. Votaw, M. M. Goodman. 2005, "Synthesis, radiosynthesis and in vivo imaging studies comparing three C-11 labeled PET ligands for mapping the serotonin transporter (SERT)". Journal of Labelled Compounds and Radiopharmaceuticals, 48, S136.
13) J. S. Stehouwer, N. Jarkas, F. Zeng, R. J. Voll, L. Williams, J. R. Votaw, M. M. Goodman. 2005, "Micropet imaging of the brain serotonin transporter with [11C]mZIENT". Journal of Labelled Compounds and Radiopharmaceuticals, 48, S149.
14) Fanxing Zeng, Nachwa Jarkas, Jeffrey S. Stehouwer, Ronald J. Voll, Larry Williams, John R. Votaw, and Mark M. Goodman. "Synthesis and biological evaluation of carbon-11 labeled 2-carbomethoxy-3-fluoro-4’-methylphenyl-nortropane: candidate PET ligand for the norepinephrine transporter". 2006, Abstracts of Papers, 231st American Chemical Society National Meeting, Atlanta, Georgia, March 26-30, MEDI-310.
15) Jeffrey S. Stehouwer, Nachwa Jarkas, Fanxing Zeng, Ronald J. Voll, Larry Williams, John R. Votaw, and Mark M. Goodman. 2006, "MicroPET imaging of the brain serotonin transporter with [11C]mZBrENT". Abstracts of Papers, 231st American Chemical Society National Meeting, Atlanta, Georgia, March 26-30, MEDI-311.
Name
Page 16
16) Mark M. Goodman, Fanxing Zeng, Nachwa Jarkas, Ronald J. Voll, Larry Williams, John R. Votaw, Leonard Howell, Clinton D. Kilts, and Charles B. Nemeroff. 2006, "Synthesis, characterization and in vivo PET imaging in non-human primates of [11C] (S,S)-MSREBOX: a new norepinephrine transporter (NET) agent". Abstracts, 58th Southeast Regional Meeting of the American Chemical Society, Augusta, Georgia, November 1-4, 1191053.
17) Jeffrey Stehouwer, Nachwa Jarkas, Fanxing Zeng, Ronald Voll, Larry Williams, John Votaw, and Mark Goodman. 2006, "MicroPET imaging of the CNS serotonin transporter with [18F]FPmZIENT and [18F]FPmZBrENT". Abstracts, 58th Southeast Regional Meeting of the American Chemical Society, Augusta, Georgia, November 1-4, 1191054.
18) J. Stehouwer, N. Jarkas, F. Zeng, R. Voll, L. Williams, J. Votaw, M. Goodman. 2006, "MicroPET imaging of the brain serotonin transporter with [18F]FEmZIENT". Journal of Nuclear Medicine, 47, 27P.
19) M. M. Goodman, N. Jarkas, J. R. Votaw, R. J. Voll, D. C. Purselle, C. D. Kilts, J. D. Bremner, C. C. Meltzer, C. B. Nemeroff. 2006, "Initial experience of high resolution brain PET imaging of human serotonin transporters (SERT) with [11C]HOMADAM". Journal of Nuclear Medicine, 47, 136P.
20) F. Zeng, N. Jarkas, J. S. Stehouwer, R. J. Voll, M. J. Owens, G. Tamagnan, L. Williams, J. R. Votaw, M. M. Goodman. 2006, "Synthesis and evaluation of a C-11 labeled reboxetine analog as a norepinephrine transporter imaging agent". Journal of Nuclear Medicine, 47, 496P.
21) M. Goodman, J. Stehouwer, N. Jarkas, R. Voll, L. Williams, J. Votaw. 2006, "In vivo characterization in non-human primates of beta FEmZIENT and beta FEmZBrENT: new serotonin transporter imaging agents: effects of selective monoamine transporter displacement using microPET". Neuroimage, 31 (Suppl. 2), T27.
22) N. Jarkas, R. J. Voll, L. A. Williams, J. R. Votaw, M. M. Goodman. 2007, "Synthesis and evaluation of a serotonin transporter ligand (SERT) PET imaging agent: [11C]BrHOMADAM". Journal of Labelled Compounds and Radiopharmaceuticals, 50, S295.
23) F. Zeng, N. Jarkas, J. S. Stehouwer, R. J. Voll, L. A. Williams, J. R. Votaw, M. M. Goodman. 2007, "Synthesis and evaluation of (S, S)-[11C]METREBOX as a norepinephrine transporter imaging agent". Journal of Labelled Compounds and Radiopharmaceuticals, 50, S290.
24) F. Zeng, N. Jarkas, J. S. Stehouwer, L. Williams, J. R. Votaw, C. D. Kilts, C. B. Nemeroff, M. M. Goodman. 2007, "18F-Labeled analogs of reboxetine as PET imaging agents for norepinephrine transporters". Journal of Nuclear Medicine, 48, 310P.
Name
Page 17
25) J. A. Nye, J. R. Votaw, N. Jarkas, D. Purselle, V. Camp, J. Bremner, M. Goodman. 2008, "Modeling of [11C]HOMADAM binding to the serotonin transporters (SERT) in healthy humans". Journal of Nuclear Medicine, 49, 118P.
26) J. A. Nye, J. R. Votaw, N. Jarkas, D. Purselle, V. Camp, J. D. Bremner, M. M. Goodman. 2008, "Kinetic modeling of human serotonin transporters with [11C]ZIENT on a high resolution brain tomograph". Journal of Nuclear Medicine, 2008, 49, 379P.
27) F. Zeng, J. Mun, N. Jarkas, J. S. Stehouwer, R. J. Voll, L. Williams, J. R. Votaw, L. Howell, M. M. Goodman. 2008, "Synthesis and evaluation of (S, S)-[11C]SMENET as a norepinephrine transporter imaging agent". Journal of Nuclear Medicine, 49, 284P.
28) F. Zeng, N. Jarkas, R. J. Voll, J. R. Votaw, L. Howell, C. D. Kilts, C. B. Nemeroff, M. M. Goodman. 2008, "MEDI224-Synthesis, characterization and in vivo imaging in nonhuman primates of a series of carbon-11 reboxetine analogs as norepinephrine transporter (NET) PET imaging agents". Abstracts of Papers of the American Chemical Society, 236: MEDI-224.
29) N. Jarkas, R. J. Voll, V. M. Camp, L. A. Williams, E. J. Malveaux, M. M. Goodman. 2009, "Synthesis of 18F-FACPC and its biological evaluation in 9L gliosarcoma cells and 9L tumor bearing rats". Journal of Labelled Compounds and Radiopharmaceuticals, 52, S194.
30) N. Jarkas, R. J. Voll, V. M. Camp, Z. Zhang, and M. M. Goodman. 2010, "Synthesis and characterization of the two enantiomers of anti-18F-FACPC as PET tumor agents". Journal of Nuclear Medicine, 51 (suppl. 2), 306P.
31) Savir-Baruch Bital, Schuster David M., Jarkas Nachwa, Master Viraj, Nieh Peter T., Halkar Raghuveer K., Nye Jonathan A., Lewis Melinda M., Roberts David L., Goodman Mark M. 2010, "Pilot evaluation of 1-amino-2-[18F]fluorocyclopentane-1-carboxylic acid (anti-2-[18F]FACPC) PET-CT in recurrent prostate carcinoma". Journal of Nuclear Medicine, 51 (suppl. 2), 237P.
32) N. Jarkas, R. Voll, V. M. Camp, L. Williams, E. J. Malveaux, Z. Zhang, M. M. Goodman. 2011, "Evaluation of 18F-FACPC stereoisomers in human tumors bearing mice". Journal of Nuclear Medicine, 52 (suppl. 1), 346-347P.
33) Jarkas Nashwa, Voll Ronald J., and Goodman Mark M. 2011, "Synthesis of N,N-dimethyl-2-(2’-amino-4’-hydroxymethyl-phenylthio)-5-(2-18F-fluorethoxy)-benzylamine (18F-FEOHOMADAM) as potential radiotracer for SERT". Journal of Labelled Compounds and Radiopharmaceuticals, 54, S266.
34) N. Jarkas, R. J. Voll, M. M. Goodman. 2012, "Development of [F-18]FPOHOMADAM as a PET radiotracer for SERT". Journal of Nuclear Medicine, 53 (suppl. 1), 435P.
Name
Page 18
35) Jarkas Nashwa, Voll Ronald J., and Goodman Mark M. 2013, "Evaluation of FEOHOMADAM as potential PET radiotracer for in vivo imaging of the SERT". Journal of Labelled Compounds and Radiopharmaceuticals, 56, S297.
36) N. Jarkas, R. J. Voll, M. M. Goodman. 2014, "Evaluation of a serotonin transporter (SERT) PET radiotracer: MeOHOMADAM ". Journal of Nuclear Medicine, 55 (suppl. 1), 1823.
